epalrestat: Clinical Trials

4 trials of epalrestat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 terminated, 1 unknown. 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Recruiting 2, Terminated 1, Unknown 1
Phase 31Recruiting 1

Follow epalrestat: new trials by email Literature Review of epalrestat trials Research Report on epalrestat

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
Epalrestat, Donafenib + Tislelizumab, HAIC - HCC - Hepatocellular Carcinoma, Diabetes
Phase 2RecruitingHaibo Shao322026-01-212026-11-10
Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.
Nebivolol+ Standard care arm, Epalrestat + Alpha Lipoic Acid +Standard care, Standard care alone - Diabetic Neuropathy Peripheral
Phase 2 / Phase 3RecruitingSt. John's Research Institute1202024-11-152025-02-04
Research of SORD-CMT Natural History and Epalrestat Treatment
Epalrestat - Charcot-Marie-Tooth Disease (CMT)
Phase 2UnknownThe Third Xiangya Hospital of Central South University302023-04-012023-04-18
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer
Epalrestat - Triple Negative Breast Cancer
Phase 2TerminatedSun Yat-sen University122017-03-012021-01-29

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Charcot-Marie-Tooth Disease (1)  ·  Diabetes Mellitus (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Haibo Shao (1)  ·  St. John's Research Institute (1)  ·  Sun Yat-sen University (1)  ·  The Third Xiangya Hospital of Central South University (1)

Countries

China (2)  ·  India (1)

Top investigators

Haibo Shao (1)  ·  Tao Han (1)